Ternary Therapeutics Raises €4.1 Million for AI-Designed Molecular Glues
Belgium-based biotech startup Ternary Therapeutics has secured €4.1 million in funding to develop a new generation of medicines that can target so‑called “undruggable” proteins. The company uses advanced AI algorithms to design molecular glues—small molecules that force harmful proteins into new interactions so they can be degraded or neutralized by the cell.
Targeting the ‘Undruggable’ with Molecular Glue Technology
Traditional small‑molecule drugs and monoclonal antibodies often fail against proteins that lack clear binding pockets or have complex, dynamic shapes. These proteins, frequently implicated in cancer, neurodegenerative disorders and rare diseases, have long been considered beyond the reach of conventional drug discovery.
Ternary Therapeutics aims to change that by engineering molecular glues that create a three‑way complex between a disease‑causing protein, a cellular partner such as an E3 ligase, and the glue molecule itself. This ternary complex can trigger the selective removal or functional silencing of the target protein, opening a new therapeutic path where no viable options previously existed.
AI-Driven Drug Discovery Platform
The startup’s platform combines machine learning, structural biology and high‑throughput screening to predict which protein surfaces can be bridged by a molecular glue and to optimize compounds for potency, specificity and safety. By simulating protein–protein interactions at scale, the system is designed to cut years from early‑stage discovery and reduce the high failure rates that plague traditional pipelines.
According to the company, the fresh capital will be used to expand its discovery engine, grow its scientific team and advance a portfolio of preclinical programs focused on oncology and other severe indications.
Positioning in the Competitive Protein Degradation Landscape
The field of targeted protein degradation has become one of the most competitive areas in modern BioTech, with large pharmaceutical companies and specialized biotechs racing to develop both PROTACs and molecular glues. Ternary Therapeutics is positioning itself as a specialist in AI‑guided glue design, a niche that could prove crucial as the industry searches for more precise and scalable approaches.
If successful, the company’s platform may extend drug discovery into vast regions of the human proteome that have remained inaccessible, potentially reshaping how the industry thinks about what is and is not “druggable.”